<DOC>
	<DOCNO>NCT02019069</DOCNO>
	<brief_summary>This phase II clinical trial study well liposomal cytarabine-daunorubicin CPX-351 ( CPX-351 ) work treat patient relapsed refractory acute myeloid leukemia myelodysplastic syndrome . Drugs use chemotherapy , liposomal cytarabine-daunorubicin CPX-35 , work different way stop growth cancer cell , either kill cell stop dividing .</brief_summary>
	<brief_title>CPX-351 Treating Patients With Relapsed Refractory Acute Myeloid Leukemia Myelodysplastic Syndrome</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine efficacy safety profile use CPX-351 older patient ( age 60 old ) : high risk myelodysplastic syndrome ( MDS ) refractory/relapsed prior hypomethylating ( HMA ) therapy ; subject great 75 year old high risk MDS HMA relapsed/refractory progress acute myeloid leukemia ( AML ) ) ; AML refractory/relapsed disease prior HMA therapy AML . SECONDARY OBJECTIVES : I . Determine duration remission follow induction therapy CPX-351 . II . Determine overall survival 12 month . III . Determine early induction mortality ( 60 day ) follow CPX-351 cohort follow induction therapy . OUTLINE : INDUCTION : Patients receive liposomal cytarabine-daunorubicin CPX-351 intravenously ( IV ) 90 minute day 1 , 3 , 5 . Patients reduce blast count achieve morphological leukemia free state ( &lt; 5 % blast ) receive second course induction therapy . Patients achieve complete remission ( CR ) CR incomplete blood count recovery ( CRi ) day 14 second course induction therapy proceed consolidation therapy . SECOND INDUCTION : Patients receive liposomal cytarabine-daunorubicin CPX-351 IV 90 minute day 1 3 . CONSOLIDATION : Beginning day 28 , patient receive liposomal cytarabine-daunorubicin CPX-351 IV 90 minute day 1 3 . Patients may receive second course 28-75 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 1 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Ability understand voluntarily give informed consent Age ≥ 60 Pathological diagnosis AML ( WHO criteria ) high risk MDS ( include int2 high risk MDS IPSS ) along one following : Patients de novo secondary MDS progression/refractoriness HMA treatment transform AML Patients MDS prior HMA treatment MDS transform AML Patients AML refractory/relapsed HMA therapy AML eligible Life expectancy &gt; 1 month Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Able adhere study visit schedule protocol requirement Laboratory value fulfil follow : Serum creatinine &lt; 2.0 mg/dL Serum total bilirubin ≤ 2.5 mg/dL . Note , patient Gilbert 's syndrome may elevate bilirubin baseline prior diagnosis AML MDS . Patients Gilbert 's syndrome include total bilirubin ≤ 2 time baseline total bilirubin . Serum alanine aminotransferase aspartate aminotransferase &lt; 3 time ULN Cardiac ejection fraction ≥ 45 % echocardiography ( transthoracic echocardiography ) MUGA scan Patients second malignancy may eligible discretion PI give acute life threaten nature untreated AML high risk MDS . Patients maintain longterm nonchemotherapy treatment , e.g. , hormonal therapy , also eligible . Patients previously undergone allogeneic hematopoietic stem cell transplant exclude study Patients previously &gt; 368 mg/m2 cumulative dose daunorubicin &gt; 368 mg/m2 daunorubicinequivalent anthracycline therapy ( example , prior treatment solid tumor ) . See appendix anthracycline equivalence table . Acute promyelocytic leukemia [ ( 15 ; 17 ) ] Any serious medical condition , laboratory abnormality psychiatric illness would prevent obtain informed consent Patients conventional intensive cytotoxic induction chemotherapy treatment specifically MDS AML exclude . Patients previously treat HMA therapy exclude Clinical evidence active CNS leukemia Patients evidence uncontrolled current myocardial impairment ( e.g . unstable ischemic heart disease , uncontrolled arrhythmia , symptomatic valvular dysfunction control medical therapy , uncontrolled hypertensive heart disease , uncontrolled congestive heart failure ) Active uncontrolled infection . Patients active infection receive treatment hemodynamically stable 48 hour may enter study Known active uncontrolled HIV hepatitis C infection Known hypersensitivity cytarabine , daunorubicin liposomal product Known history Wilson 's disease copperrelated disorder Other medical psychiatric illness organ dysfunction laboratory abnormality opinion investigator would compromise patient 's safety interfere data interpretation Laboratory abnormality : Serum creatinine ≥ 2.0 mg/dL Serum total bilirubin &gt; 2.5 mg/dL . Note , patient Gilbert 's syndrome may elevate bilirubin baseline prior diagnosis AML MDS . Patients Gilbert 's syndrome exclude total bilirubin &gt; 2 time baseline total bilirubin . Serum alanine aminotransferase aspartate aminotransferase &gt; 3 time ULN</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>